Heterocyclic Compounds

Matches 451 - 500 out of 34,169	< 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 >

Document	Document Title
WO/2023/249563A1	COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION The disclosure provides for compounds and methods for inhibiting protein kinase, membrane associate tyrosine/threonine 1 (PKMYT1).
WO/2023/246656A1	SOS1 PROTEOLYSIS TARGETING CHIMERA, AND COMPOSITION, PREPARATION AND USE THEREOF The present invention belongs to the technical field of medicinal chemistry, and relates to an SOS1 proteolysis targeting chimera and a composition, a preparation and the use thereof. Specifically, the general formula structure of the ch...
WO/2023/247552A1	MICROBIOCIDAL BICYCLIC HETEROCYCLIC CARBOXAMIDE DERIVATIVES A compound of formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
WO/2023/250156A1	4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF 4-Alkoxypyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 4-alkoxypyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof...
WO/2023/249994A1	METHODS AND MATERIALS FOR TREATING CANCER This document relates to methods and materials involved in treating a mammal (e.g., a human) having cancer. For example, bifunctional molecules (e.g., protein targeting chimeras (PROTACs)) that include (a) a targeting moiety that binds t...
WO/2023/249980A1	METHODS OF MAKING MODIFIED BTK INHIBITORS Provided herein are BTK inhibitors containing piperidine modified at the 3-position. Further disclosed are methods of making and using said BTK inhibitors.
WO/2023/250083A1	SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido...
WO/2023/247670A1	NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS The present invention provides compounds of formula (I) CB (I) or pharmaceutically acceptable salts thereof, wherein R3 to R5, R4a, B and C are as described herein, compositions including the compounds, processes of manufacturing the com...
WO/2023/250335A1	1,4-DIPHENYL-1 H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1 H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER The present disclosure relates to compounds of Formula (I): The compounds disclosed herein are useful for modulating PD-1 activity, PD-L1 activity (programmed cell death protein 1), and/or the PD-1/PD-L1 interaction and may be used in th...
WO/2023/247595A1	PYRAZOLOPYRAZINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
WO/2023/250084A1	USP1 INHIBITORS AND USES THEREOF The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
WO/2023/250431A2	MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain ...
WO/2023/247592A1	5-(4-FLUOROPHENYL)-2,3-DIHYDRO-1H-IMIDAZO[1,2-A]IMIDAZOLE DERIVATIVES AS ALK INHIBITORS FOR THE TREATMENT OF FIBROSIS The present invention relates to 5-(4-fluorophenyl)-2,3-dihydro-1H- imidazo[1,2-a]imidazole derivatives of formula (I) as ALK5 inhibitors (transforming growth factor 3 (TGF3) type 1 receptor) for the treatment of fibrosis, such as e.g. p...
WO/2023/247593A1	PYRROLOPYRIDINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
WO/2023/249370A1	NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING SAME The present invention relates to: a novel aromatic heterocyclic compound that can be used in an organic light-emitting diode; and an organic light-emitting diode including same.
WO/2023/246631A1	PREPARATION METHOD FOR DIAZABICYCLO PEPTIDOMIMETIC DERIVATIVE AND USE THEREOF Disclosed are a preparation method for a diazabicyclo peptidomimetic derivative and use thereof. The preparation method comprises: using an intramolecular nucleophilic substitution reaction in which sulfonamide is taken as a nucleophilic...
WO/2023/247590A1	TRIAZOLOPYRIDINE AND BENZOISOXAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS The disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
WO/2023/250181A1	TRIAZOLE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D Provided is a compound having the structure of Formula (1) or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof, wherein A, B, Ri, R2, R3, R4, R5, R6, R7, m, 11, p, and y are as defined herein, for use in methods fo...
WO/2023/246846A1	NON-CHELATING AND NON-REDUCING FERROPTOSIS INHIBITOR, METHOD FOR PREPARING SAME, AND USE THEREOF The present invention provides a compound represented by formula (I), a method for preparing same, and use thereof. The compound or a pharmaceutically acceptable salt thereof or a stereoisomer thereof is non-chelating and non-reducing, a...
WO/2023/250082A2	SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido...
WO/2023/246154A1	NITROGEN-CONTAINING COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS The present application relates to the technical field of organic electroluminescent materials, and provides a nitrogen-containing compound, an organic electroluminescent device comprising same and an electronic apparatus. The compound o...
WO/2023/249996A1	VACCINE ADJUVANTS A vaccine composition can include an adjuvant compound and a pharmaceutical carrier having the adjuvant. The vaccine composition can also include an immunological vaccine agent in the pharmaceutical carrier with the adjuvant. The immunol...
WO/2023/250518A2	CATALYST FOR POLYMERIZATION OF CYCLIC ETHER AND CYCLIC ESTER MONOMERS AND THE RESULTING POLYMERS Provided herein are novel catalyst complexes useful in ring-opening polymerization of lactones particularly β-lactones. The catalyst complexes have a structural formula that includes a ligand and metal precursor of zinc and aluminum. Th...
WO/2023/246925A1	ESTER COMPOUNDS AND USE THEREOF Disclosed in the present invention are compounds or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers or isotope labeled compounds thereof. The compounds are as shown in formula (I)....
WO/2023/246777A1	K-RAS MUTANT PROTEIN INHIBITORS The invention relates to KRAS mutant protein inhibitors of formula (I) or formula (II), a composition containing the same and the use thereof.
WO/2023/243686A1	DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF The present invention provides a compound that exhibits a PLD-inhibitory activity.　The present invention provides a compound having the following structural formula or the like, or a pharmaceutically acceptable salt thereof. (Each symb...
WO/2023/242384A1	CRYSTALLINE FORM OF IBRUTINIB The present invention relates to crystalline form of ibrutinib, designated as Form K1, and processes for its preparation.
WO/2023/244604A1	TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and m...
WO/2023/244562A1	CRYSTALLINE FORMS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1- YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENI TRILE Provided herein are substantially crystalline solid forms of 2-[3-[4- amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin- 1 - yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperaz in-1- yl]pent-2-enenitrile (identified he...
WO/2023/241322A1	HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF Provided are heterocyclic derivatives as shown in Formula (I), pharmaceutical compositions comprising them, a process for their preparation, and their use as therapeutic agents.
WO/2023/241552A1	SALT AND/OR CRYSTAL FORM FOR COMPOUNDS AS CASEIN KINASE INHIBITORS The present disclosure provides salt and/or crystal form for compounds, especially for compounds as casein kinase inhibitors.
WO/2023/244615A1	AZAQUINAZOLINE PAN-KRAS INHIBITORS The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use th...
WO/2023/242845A1	SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (CoLDR) COMPOUNDS Provided herein electrophiles (I) comprising a sulfamate group for covalent ligand-directed release chemistry (CoLDR). Formula(I).
WO/2023/241598A1	AROMATIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF IN PREPARATION OF ESTROGEN RECEPTOR DEGRADER The present invention provides an aromatic compound, a method for preparing same, and use thereof in the preparation of an estrogen receptor degrader, and belongs to the technical field of chemical medicines. The aromatic compound is a c...
WO/2023/241644A1	FIVE-MEMBERED RING-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Disclosed in the present invention are a five-membered ring-fused six-membered compound, a preparation method therefor, and a pharmaceutical composition and the use thereof. Provided in the present invention is a compound as represented ...
WO/2023/245123A2	MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain ...
WO/2023/245091A1	PYRIDAZINONE-DERIVED COMPOUNDS FOR THE MODULATION OF MYC AND FOR MEDICAL USES Compositions, systems, and methods are described herein for the modulation, and in particular the reduction or inhibition, of expression or activity of MYC in a cell, animal or human subject. Such compositions, systems, and methods are u...
WO/2023/242809A1	CRYSTALLINE FORMS OF 4-[(5-CHLOROPYRIDIN-2-YL)METHOXY]-1-[3-(PROPAN-2-YL)-1H,2H,3H,4H,5H-[1,4]DIAZEPI NO[1,7-A]INDOL-9-YL]-1,2-DIHYDROPYRIDIN-2-ONE AND SALTS THEREOF, METHOD OF PREPARATION, AND USES THEREOF The present disclosure relates to hydrochloride salts of 4-[(5-chloropyridin-2-yl)methoxy]-1-[3-(propan-2-yl)-1H,2H,3 H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl]-1,2- dihydropyridin-2-one (Compound 1), a potent, and orally active selective ...
WO/2023/241551A1	SALT AND/OR CRYSTAL FORM FOR COMPOUNDS AS CASEIN KINASE INHIBITORS The present disclosure provides salt and/or crystal form for compounds, especially for compounds as casein kinase inhibitors.
WO/2023/244815A1	MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME Described herein, in part, are compounds that mediate the degradation of casein kinase 1α (CK1α), and are therefore useful in the treatment of various disorders, such as cancer.
WO/2023/244059A1	METHODS OF TREATING CANCER USING DUAL ANDROGEN RECEPTOR AND PDE5 INHIBITOR COMPOUNDS The present disclosure provides a method of treating a subject with cancer by using an androgen receptor (AR) inhibitor and phosphodiesterase 5 (PDE5) inhibitor compound, and compositions comprising the same. The compounds of this disclo...
WO/2023/242631A1	ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME The present disclosure relates compounds for inhibiting ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP-1), or a pharmaceutically acceptable salts thereof.
WO/2023/244996A2	HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the presen...
WO/2023/244806A1	COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A Disclosed are compounds of formula I, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, that are useful for modulating or degrading protein which is expressed from one or more SWI/SNF-related matrix-assoc...
WO/2023/241627A1	CDK8/19 DUAL INHIBITORS AND METHODS OF USE THEREOF The disclosure provides for compounds and methods for modulating or inhibiting CDK8/19.
WO/2023/245053A1	SOLID FORMS OF A JAK INHIBITOR AND PROCESS OF PREPARING THE SAME The present disclosure is related to solid forms of ruxolitinib di-hydrate and ruxolitinib free base, process of preparing the same, and compositions comprising the same.
WO/2023/242597A1	BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
WO/2023/244713A1	QUINAZOLINE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF The invention provides novel quinazoline derivatives, substituted at the C4 position with an unsubstituted or substituted, 3- to 10-membered monocyclic, bicyclic or bridged nitrogen heterocyclic ring moiety, that are shown to be potent a...
WO/2023/241950A1	MIXTURES OF COMPOUNDS HAVING IMPROVED SOLUBILITY FOR USE AS MARKERS The present invention relates to mixtures of compounds of the formula (Ia), (Ib), (Ic) and (Id), a process for its preparation and its use in security applications; for brand protection or as marker for liquids. The compounds of formula ...
WO/2023/241620A1	BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Provided are compounds, compositions, methods, use for preventing or treating various conditions, disorders or diseases. In some embodiments, a condition, disorder or disease is cancer.

Matches 451 - 500 out of 34,169	< 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 >